Alzheimer's disease (AD) is caused by a cascade of changes to brain integrity. Neuroimaging biomarkers are important in diagnosis and monitoring the effects of interventions. As memory impairments are among the first symptoms of AD, the relationship between imaging findings and memory deficits is important in biomarker research. The most established magnetic resonance imaging (MRI) finding is hippocampal atrophy, which is related to memory decline and currently used as a diagnostic criterion for AD. While the medial temporal lobes are impacted early by the spread of neurofibrillary tangles, other networks and regional changes can be found quite early in the progression. Atrophy in several frontal and parietal regions, cortical thinning, and white matter alterations correlate with memory deficits in early AD. Changes in activation and connectivity have been detected by functional MRI (fMRI). Task-based fMRI studies have revealed medial temporal lobe hypoactivation, parietal hyperactivation, and frontal hyperactivation in AD during memory tasks, and activation patterns of these regions are also altered in preclinical and prodromal AD. Resting state fMRI has revealed alterations in default mode network activity related to memory in early AD. These studies are limited in part due to the historic inclusion of patients who had suspected AD but likely did not have the disorder. Modern biomarkers allow for more diagnostic certainty, allowing better understanding of neuroimaging markers in true AD, even in the preclinical stage. Larger patient cohorts, comparison of candidate imaging biomarkers to more established biomarkers, and inclusion of more detailed neuropsychological batteries to assess multiple aspects of memory are needed to better understand the memory deficit in AD and help develop new biomarkers. This article reviews MRI findings related to episodic memory impairments in AD and introduces a new study with multimodal imaging and comprehensive neuropsychiatric evaluation to overcome current limitations.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting from pathological changes which typically spread through brain networks in a predictable pattern. AD pathology leads to early decline in memory, and some pathology can be detected years before measurable cognitive or functional change. At present, there are no disease-modifying treatments, and symptomatic treatment is limited in efficacy. Trials of novel therapeutics increasingly target the earliest brain changes, when a disease-modifying trajectory could potentially result in reduction or elimination of clinical impact. Memory measures remain an important way of assessing such clinical impact and are required in clinical trials in the United States [1] .
Accurate diagnosis of AD was, until recently, confirmed only at autopsy. Today, there are several imaging biomarkers measuring neurodegeneration and amyloid b (Ab) deposition in the brain to support the diagnosis [2] . Atrophy on structural magnetic resonance imaging (MRI), hypometabolism on fluorodeoxyglucose positron emission tomography (FDG-PET), and increased levels of craniospinal fluid (CSF) total and phosphorylated tau are used to assess neurodegeneration. CSF Ab42 and Ab PET, on the other hand, are used to assess Ab pathology. Preclinical studies focus on groups at risk for AD, as defined by the apolipoprotein E (APOE) status or examine cognitively normal control (CNC) performance in the context of other AD biomarkers, such as CSF Ab. Large, shared, multisite, longitudinal multimodal data sets such as the AD Neuroimaging Initiative and similar studies initiated in Asia, Europe, and Australia allow for widespread exploration of structural and functional magnetic resonance imaging (fMRI) and PET data in addition to clinical, cognitive, and fluid biomarker data across the spectrum of disease. While there are several limitations, these data sets are an important resource in understanding imaging biomarkers in AD.
Memory is a complex construct. AD has an early and specific impact on episodic memory (i.e., the ability to learn and remember new information) [3] , which can broadly be subdivided into encoding (or learning), recall, and recognition. Different types of stimuli (e.g., words, faces, and shapes) and memory tests (e.g., single trial and multi-trial presentations, free and prompted recall) can be used to detect deficits in these aspects of memory, and typically used measures often differ between clinical and research settings. Nonetheless, many studies of AD MRI biomarkers and biomarker candidates have included memory measures as correlates or validating factors.
At present, despite exploration of imaging biomarkers for AD, few have become widely accepted and approved for clinical use, and most remain experimental. In this targeted review, we focused on MRI studies. Following the conceptualization of AD as a biological and clinical continuum by Aisen et al [4] , we assessed the MRI findings within preclinical (clinically normal individuals with evidence of AD pathology), and clinical (mild cognitive impairment [MCI] or prodromal AD, and AD dementia [ADD]) phases of AD. The transition between these phases is subtle, and individuals may report cognitive decline even when neuropsychological testing does not suggest any impairment. As episodic memory is the first cognitive domain to be affected along the course of AD, we aimed to investigate the association between MRI findings and episodic memory performance specifically. Current diagnostic criteria of MCI (prodromal AD) and ADD are based on clinical history, neuropsychological testing, and neurologic and psychiatric examinations [5, 6] . Imaging methods, CSF, and blood tests are used only to support the diagnosis and to exclude other dementia causes. Nevertheless, subtle findings on MRI have been reported years before the onset of clinical symptoms. Thus, imaging findings correlating with the clinical profile may help identify underlying mechanisms and therapeutic targets for the debilitating memory deficit in AD.
Structural MRI
Aging is associated with a slow decline in both white matter (WM) and gray matter (GM) volumes, and this atrophy rate is increased in AD [7] . Although GM atrophy has been more frequently assessed in AD, structural MRI approaches also allow for the assessment of cortical thickness, as well as shape and WM alterations. This section will focus on studies investigating the relationship between episodic memory performance and structural changes in GM and WM using different imaging analysis approaches ( Table 1 ). Structural differences between CNC and participants within AD spectrum without any episodic memory associations are beyond the scope of this review and will not be discussed.
GM changes
Hippocampal atrophy is included in the 2011 National Institute on Aging criteria for ADD and MCI due to AD [3, 5] . Before the advent of Ab PET imaging, hippocampal volumetric changes that can be determined noninvasively and relatively cheaply using MRI were one of the earliest detectable imaging changes in AD. These changes can be quantified using NeuroQuant, an Food and Drug Administration-approved imaging processing tool [42] . Decline in hippocampal volume and thickness has been consistently associated with memory deficits in AD continuum. In preclinical AD, hippocampal and entorhinal cortex volume, and hippocampal and parahippocampal thickness have been associated with verbal memory [9, 12, 30] . There have also been reported associations between reduced medial temporal lobe (MTL) volume in CNC with AD risk factors and future memory decline [8] . Further along the course of the disease, in MCI and ADD, decline in hippocampal volume and MTL thickness was associated with worsening in verbal memory [13, 16, 19, 21, [23] [24] [25] [26] [27] 29, [33] [34] [35] 39, 40] . Although less extensively studied, visual memory has been associated with hippocampal volume in amnestic MCI (aMCI) [39] . Studies of hippocampal subregions revealed that CA1 volume declines within hippocampus were particularly related with recall performance in aMCI and ADD [26, 29, 37] .
With time, GM changes in AD spread outside the MTL. Extratemporal regions implicated in episodic memory decline include the posterior cingulate gyrus (PCG)/precuneus [28, 30, 31] and middle frontal gyrus [27, 28] . Both atrophy and thinning of these regions were associated with memory decline. In MCI patients, who converted to ADD over time, decreased inferior frontal gyrus volume was associated with the verbal memory decline [38] , suggesting extratemporal involvement may be predictive of disease progression.
WM changes
While AD is a disease primarily associated with GM loss, concomitant WM change has a role in cognitive expression. Abbreviations: MCI, mild cognitive impairment; APOE ε4, apolipoprotein E ε4; CNC, cognitively normal control; aMCI, amnestic mild cognitive impairment; ADD, Alzheimer's disease dementia; naMCI, nonamnestic mild cognitive impairment; CVLT, California Verbal Learning Test; RAVLT, Rey Auditory Verbal Learning Test; WMS-R, Wechsler Memory Scale-Revised; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; CERAD-WL, CERAD-Word list; BVMT-R, Brief Visuospatial Memory Test-Revised; CANTAB, Cambridge Neuropsychological Test Automated Battery; RCFT, Rey Complex Figure Test ; DMS48, delayed matching to sample-48 items; ADAS-Cog, Alzheimer's Disease Assessment Scale-cognitive subscale; HVLT-R, Hopkins Verbal Learning Test-Revised; HC, hippocampus; FDG-PET, fluorodeoxyglucose positron emission tomography; WM, white matter; DTI, diffusion tensor imaging; VBM, voxel-based morphometry; ROI, region of interest; SPECT, single-photon emission computed tomography; DBM, deformation based morphometry; WMH, white matter hyperintensity; MTL, medial temporal lobe; CA, cornu ammonis; CA1-SP, CA1-stratum pyramidale; CA1-SRLM, CA1-stratum radiatum/stratum lacunosum-moleculare; DG/CA3, dentate gyrus/CA3; PCG, posterior cingulate gyrus; PiB PET, Pittsburgh compound B PET; GM, gray matter; MD, mean diffusivity; R, right; L, left; FA, fractional anisotropy. Diffusion tensor imaging metrics characterizing brain WM integrity are commonly affected in the AD continuum. Increased WM integrity for the whole brain was associated with better memory performance in CNC, MCI, and ADD, suggesting whole brain fractional anisotropy might be an overall marker of severity, rather than a specific measure [15, 36] . Genetic status may mediate the relationship between MRI findings and cognition. In APOE ε4 carriers, loss of entorhinal WM integrity was related to worse memory performance [10] . However, other factors such as lower baseline MTL WM integrity have also been identified as predictors of memory decline in CNC converting to aMCI in 2 years [11] , which can have the potential to be used as a biomarker for early diagnosis. MTL WM volume and integrity continued to have positive correlations with memory in aMCI and ADD [14, 17, 18, 26, 32, 34] . Similar to GM changes, which include both MTL and extratemporal regions, precuneus WM volume reduction was also associated with worsened memory in aMCI [18] . Several fasciculi including uncinate, fornix, and cingulum, which are connected to medial temporal regions, were implicated in studies associating fiber density and memory [20, 22, 41] . In addition to these WM volume and integrity changes, Fujishima et al [19] reported that increased number of WMHs, pointing to increased vascular impairment, in the bilateral periventricular regions was related to worse recall performance in MCI.
Besides these more common MRI techniques, other approaches including diffusion kurtosis imaging, relaxometry, and magnetic transfer imaging may prove to be helpful in investigating WM integrity with high accuracy for whole brain mapping [43, 44] . However, the number of studies using these approaches within the AD continuum is currently relatively small. In summary, structural imaging studies show that hippocampal atrophy, which is closely related to episodic memory performance, is an established neurodegeneration biomarker in AD. Volume and cortical thickness of several additional regions, including PCG and precuneus, require further attention in terms of relationship to memory performance. WM changes, including loss of WM integrity in MTL and fasciculi connected to MTL assessed by formal diffusion tensor imaging metrics and hyperintensities in posterior regions of the brain, were also related to memory decline and should be assessed further in confirmed AD samples.
Functional MRI
fMRI is an indirect measure of brain activity relying on blood-oxygen-level dependent response, which is a proxy for neural activation. fMRI can be separated into taskbased, when a participant is asked to engage in a task during scanning, or resting state, when the participant is asked to lie still without engaging in a task. In this section, we will summarize studies finding differences between those with preclinical or clinical AD and CNC, either on memory tasks during fMRI, or with resting state fMRI interpreted in relation to memory scores.
Task-based fMRI
Many studies have implemented task-based fMRI to investigate memory-related activation patterns in AD (Table 2) . A variety of tasks have been used, most notably association tasks that pair two different stimuli (e.g., a face and a name). Whereas most studies include verbal stimuli, several studies use nonverbal stimuli (e.g., scene and picture encoding). Results of these studies support and extend the previously mentioned structural MRI findings.
Preclinical AD
Individuals with AD risk exhibit changes in bloodoxygen-level dependent responses even before the onset of memory deficits. These changes are nonlinear, with different activation patterns in MTL and heightened activation in frontal lobes sometimes reported. For example, reduced deactivation of PCG/precuneus [45, 49, 82] , increased frontal activation [45] , and altered MTL activation have all been reported, with one study reporting hyperactivation [45] and another reporting hypoactivation in preclinical APOE ε4 carriers [47] . Both presenilin 1 mutation carriers and individuals with subjective memory impairment had hippocampal hypoactivation [46, 48] . Frontal hyperactivation was also observed in individuals with subjective memory impairment [48] . These activation patterns in preclinical AD are suggestive of compensatory mechanisms within these regions which are capable of maintaining normal levels of cognition.
Mild cognitive impairment
Both hypoactivation [50, 51, 57, 59, 61, 62, 64, 77] and hyperactivation [53, 78, 80, 83] of the MTL during memory tasks have been reported in MCI. This difference may be a result of the particular memory process being assessed, as suggested by a study by Trivedi et al [55] reporting hypoactivation of parahippocampal cortices during encoding and hyperactivation of hippocampus during recognition in aMCI. A study showing CA3/dentate hyperactivation and entorhinal hypoactivation also suggested that discrepant findings in MTL may be caused by different activation patterns in MTL structures and hippocampal subregions [60] . The discrepancy may also be due to the mixed sample of MCI patients included in the studies. For example, MCI patients with lower dementia score as determined by Clinical Dementia Rating had hippocampal hyperactivation and decreased default mode network (DMN) deactivation, whereas the activation pattern was completely opposite in MCI patients with higher dementia scores [79] .
Similar to MTL, while some studies show reduced PCG/ precuneus activation [50, 61, 64] , some report hyperactivation or reduced deactivation within these regions [53, 81, 82, 84] . PCG/precuneus is part of the DMN, and hyperactivation of these areas is possibly due to reduced deactivation of the DMN while performing a task. Frontal cortex activation is usually reduced [50, 51, [54] [55] [56] [57] 59, 61, 63] while several studies show hyperactivation in several frontal regions including precentral gyrus [51, 52, 59, 64] . Dividing the MCI sample into two groups depending on cognitive performance, Clement and Belleville [58] revealed that frontal activation during a verbal memory task was decreased in MCI patients with more cognitive decline. Temporoparietal regions are also reported to be affected with some studies showing hypoactivation of these regions during picture or scene encoding tasks [55] [56] [57] 64] and some reporting hyperactivation [61] . These findings suggest that future studies may benefit from better defined samples instead of including different types of MCI (aMCI and naMCI) patients with various levels of dementia.
Alzheimer's disease dementia
In ADD, MTL hypoactivation [65] [66] [67] 69, 70, 72, [77] [78] [79] 81] and PCG/precuneus hyperactivation [69, 81] or reduced deactivation [68, 75, 82] are the most consistent findings. Affected regions are not limited to these more commonly reported areas in the brain. Activation in frontal regions including prefrontal and motor areas were altered during verbal or visual encoding and recognition [66, 73, 76] . Although results are not consistent, there seems to be a tendency for frontal hyperactivation [67, 69, 72, 74, 75] .
Overall, task-based fMRI findings suggest that episodic memory tasks lead to MTL hypoactivation, frontal hyperactivation, and reduced PCG/precuneus deactivation in ADD. Although preclinical AD and MCI samples have activation differences within these regions, the results are not consistent yet to provide early diagnosis or disease-tracking biomarker candidates. The discrepancy of the results appear to be caused by inclusion of mixed patient samples, distinct verbal and visual memory tasks, and implementing different analysis methods for imaging. In conclusion, task-based fMRI seems like a promising tool which can detect early changes along the AD continuum requiring further investigations for biomarker research in AD.
Resting state fMRI
By its nature, resting state fMRI (rsfMRI) does not involve a task, but the connectivity metrics calculated from these data can be used to assess relationships with memory tasks completed outside of the scanner (Table 3 ). This technique allows the investigation of functional connectivity between two regions and/or within specific networks impaired in AD.
Preclinical AD
In APOE ε4 carriers, verbal memory decline was related to reduced anterior and posterior connectivity as shown by whole brain dynamic functional connectivity [87] . Studies using seed-based analysis reported that verbal memory decline was associated with reduced left medial temporal gyrus; and DMN and executive control network connectivity [85, 86] . When episodic memory performance related to structural changes within DMN regions, reduced deactivation shown by task-based fMRI and connectivity decline of this network shown by rsfMRI are considered altogether, this network appears to play a significant role in AD and could be used for early diagnosis.
Clinical AD
The relationship between DMN connectivity reduction and episodic memory decline persisted in MCI [88, 93, 101, 104] and ADD [100, 101, 104] . Longitudinal studies showed that the progression of memory decline in aMCI was related to the decline of functional connectivity between posterior cingulate cortex and other DMN regions [88] , precentral gyrus [99] , hippocampal formation [94] , and hippocampus subregions [89] . Xie et al investigated the connectivity between regions with atrophy in aMCI and revealed that both atrophy of hippocampus, precuneus, insula, postcentral gyrus, and frontal regions and connectivity reduction between these regions were associated with worse memory performance. Decreased MTL connectivity with locus coeruleus [95] , frontal medial cortex, and lateral occipital cortex [97] was associated with worse verbal memory scores. Focusing on insula subregions revealed that increased intrinsic connectivity of insula was also associated with better memory performance [92] . Combining both rsfMRI and FDG-PET approaches, Franzmeier et al [98] revealed an interaction between functional connectivity of frontal cortex and precuneus hypometabolism. With decreased frontal connectivity, precuneus hypometabolism was associated with reduced memory performance, whereas this association was lower at higher levels of frontal connectivity in aMCI. This study suggests that memory performance does not only rely on functional connectivity but also metabolism of DMN regions. Finally, in contrast to findings in aMCI, worse memory performance was associated with increased middle frontal gyrus and parahippocampus connectivity [103] , and intrinsic hippocampal connectivity [102] in ADD.
To summarize, rsfMRI findings have revealed that MTL and DMN connectivity changes in AD are related to episodic memory. Reductions in DMN connectivity are closely related to memory decline, whereas MTL connectivity results are not that consistent throughout the AD continuum. Whereas preclinical and prodromal AD samples have reduced connectivity in association with worse memory performance, this pattern in reversed in ADD. Although DMN findings are rather consistent, there is still a need for more studies with sufficient power before rsfMRI can provide a reliable AD biomarker or tracking tool. Future studies may benefit from combining rsfMRI with other imaging techniques, including FDG-PET, and defining patient samples better by supporting the clinical criteria with established structural MRI, PET, and CSF findings.
Molecular MRI
Proton magnetic resonance spectroscopy can be used to assess changes in cell-specific metabolites, including choline, creatine, glutamine, glutamate, glutathione, N-acetyl aspartate (NAA), and myo-inositol. Levels of NAA, reflecting neuronal loss or dysfunction, decrease in AD; whereas increased myo-inositol levels, reflecting glial cell activation, have been reported in MCI and AD [105, 106] . Glutathione is an intracellular antioxidant in the brain and has yet to be extensively studied in AD [107] . In addition, there are only a few studies evaluating the association between these metabolite alterations and memory performance in particular ( Table 4) .
Levels of NAA in MTL have been consistently reported to have positive associations with verbal memory performance both in MCI and ADD [108, 109, [111] [112] [113] . In addition to the positive correlation between PCG NAA and verbal memory scores [110] , NAA within this regions decrease along the AD continuum [114] . Levels of NAA were shown to decrease with age (as shown by the difference between young and old CNCs) and AD progression. Patients with ADD had the lowest NAA and creatine concentration, followed by aMCI patients, whereas young CNCs had the highest concentration in PCG/precuneus. As myo-inositol increases in AD, it also seems to be negatively correlated with verbal memory in MCI and AD [110, 113] . These results suggest that increased neuronal dysfunction coupled with glial cell activation play a role in the verbal memory deterioration in MCI and AD. Elevated glutathione levels with decreased memory performance are suggestive of early compensation in MCI [107] . These molecules may prove to be markers to track disease progression with future longitudinal studies investigating the course of the levels of these molecules within specific regions in association with cognitive decline.
Arterial spin labeling MRI
Arterial spin labeling MRI measures cerebral blood flow (CBF), which is a more direct evaluation of brain physiology compared with the blood-oxygen-level dependent response measured by fMRI. A small number of studies on this MRI technique reported that the CBF alterations are associated with episodic memory within the AD continuum (Table 5) .
Decreases in MTL CBF are detected even in the preclinical phase in individuals with AD risk [115] . Structures of MTL and PCG/precuneus CBF are closely associated with verbal memory performance in this sample of individuals. Individuals with positive Ab, subjective cognitive decline, and APOE ε4 carriers have a decline in verbal memory performance coupled with increased CBF [117] [118] [119] . Although there are no directional data regarding this association, this may be suggestive of a compensatory response within these regions aimed toward improving the performance.
In line with other MRI approaches, MCI patients show decreased CBF responses in MTL and PCG/precuneus, which correlate with the verbal memory performance [122, 123] . Superior occipital lobe CBF is reduced when tasks demanding visual encoding are used [123] .
Owing to diversity of the episodic memory tests used in the current studies, and the small number of studies to date, conclusions about how arterial spin labeling relates to episodic memory across the AD process would be premature. However, results to date suggest that arterial spin labeling magnetic resonance imaging holds a potential to provide biomarkers which can be used in early diagnosis and progression of AD.
Limitations and future directions
Existing literature suggests that MRI, widely available in clinical and research settings, may offer several potential biomarkers related to episodic memory impairment in AD. Structural and functional alterations in different regions may increase the predictive value of hippocampal atrophy assessed by MRI for AD diagnosis. As MRI findings correlate with episodic memory deficits, they have the potential to offer more insight into the etiology of the disease and more utility for tracking progression over time.
Nevertheless, there are several limitations to using MRI in AD. Imaging is expensive, requires skilled staff for acquisition and analysis, and is time consuming. In most of the studies, cohort sizes tend to be small, limiting confidence in results [28, 31, 65, 67, [69] [70] [71] [72] [73] [74] [77] [78] [79] [80] [81] 124, 125] . The existence of large shared data sets such as AD Neuroimaging Initiative mitigates this to some extent and has been extremely useful in better understanding structural aspects of the disease. However, AD Neuroimaging Initiative is also limited in functional imaging data as it includes only rsfMRI and no task-based sequences. In addition, the neuropsychological battery includes only verbal memory testing. This is also true of many clinical research studies that limit our understanding of the relationship between rsfMRI and nonverbal measures. This differs from the task-based literature, where many tasks found to differentiate between AD and other cohorts involve nonverbal stimuli such as faces and scenes.
Another limitation is the use of clinical criteria for probable AD in most of the mentioned studies. For example, only a few used hippocampal atrophy, CSF Ab, or PET to support the AD diagnosis [20, 26, 41, 73, 78, 80, 90, 95, 97, 98] . Remy et al [20] included hypometabolism assessed by FDG-PET, medial temporal atrophy shown by MRI, and the level of phospho-tau and Ab-tau index to confirm the AD diagnosis within their patient sample. The rest of the studies included in our review relied only on clinical criteria. Without the integration of supporting biomarkers, the positive predictive value of clinical diagnostic criteria is rather limited with poor negative predictive value [126] . If biomarkers revealing Ab deposition and neurodegeneration are present at the same time as clinical criteria, likelihood of AD dementia is significantly increased [127] . Thus, whenever possible, these biomarkers should be implemented to reliably define study samples.
Although investigating differences on a whole brain level may help discover other regions implicated in episodic memory performance, these analyses may not be efficient in detecting subtle changes. Compared with region-ofinterest analyses, whole brain analyses require spatial blurring and corrections for multiple comparisons leading to decline in power to detect small changes [45] . More powerful analysis methods should be favored in biomarker research to obtain more reliable results.
Moving forward, it seems that multimodal biomarker studies that use both Ab and/or tau PET ligands and both structural and functional MRI might become more common in AD. Our own research supported by a Center for Biomedical Research Excellence award from the National Institute of General Medical Sciences will use Ab PET, resting state fMRI, and neuropsychological testing including verbal, nonverbal, and navigational memory techniques in an attempt to fill some of the gaps in the current understanding of AD. Future work building from the current protocol will incorporate task-based fMRI to further understand taskbased network connectivity in relation to the Ab status and neuropsychological performance. Using multimodal imaging and including nonverbal memory tests in addition to verbal tests will expand on previous imaging studies. Navigational tasks used in animal studies are rarely implemented in human research, limiting the translational value of these studies. Thus, by using navigational tasks, we aim to overcome this existing limitation.
Conclusions
Several MRI and fMRI metrics, including hippocampal atrophy, hold the potential to become AD biomarkers and may be more relevant to the preclinical stages. However, most imaging studies include only one modality with either verbal or nonverbal memory tasks, which prevent generalized conclusions to be drawn from their findings. Investigating the underlying pathology of AD through the combination of multimodal imaging and extensive neuropsychological evaluation may help in early diagnosis and in testing the effectiveness of novel therapeutics. Longitudinal studies with larger participant samples, where clinical AD diagnosis has been supported by multiple biomarkers, could provide a better understanding of the disease.
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RESEARCH IN CONTEXT
1. Systematic review: Memory impairments are among the most common and early symptoms of Alzheimer's disease (AD). Structural and functional changes assessed by magnetic resonance imaging are related to memory performance.
2. Interpretation: Magnetic resonance imaging findings in AD associated with memory performance can be used as potential biomarkers in the future. However, current conflicting results are probably due to the fact that most studies use limited memory tests in small patient samples with probable AD diagnosis.
3. Future directions: More extensive neuropsychological batteries should be implemented in larger patient groups with multimodal imaging. The diagnosis for AD should be supported by currently available biomarkers to achieve more reliable results.
